# Clinical Prediction Models for Treatment Outcomes in Newly-diagnosed Epilepsy

# Corey Ratcliffe<sup>1,2</sup>, Vishnav Pradeep<sup>3</sup>, Anthony Marson<sup>1</sup>, Simon S. Keller<sup>1,4</sup>, and Laura J. Bonnett<sup>3</sup>

# 29.11.2023

 <sup>1</sup> Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK
 <sup>2</sup> Department of Neuro Imaging and Interventional Radiology, National Institute of Mental Health and Neuro Sciences, Bangalore, India
 <sup>3</sup> Department of Mental Department of Mental Department of Mental Health and Neuro Sciences, Bangalore, India

<sup>3</sup> Department of Health Data Science, University of Liverpool, UK

<sup>4</sup> The Walton Centre NHS Foundation Trust, Liverpool, UK

\* Correspondence Email: <corey.ratcliffe@liverpool.ac.uk>

\* Correspondence Address: Liverpool BRAIN Lab, Room F20 (space ref 1/008), University of Liverpool Cancer Research Centre, 200 London Road, Liverpool, U.K., L3 9TA

Vishnav Pradeep <V.Pradeep@liverpool.ac.uk>

Anthony Marson <A.G.Marson@liverpool.ac.uk>

Simon S. Keller <Simon.Keller@liverpool.ac.uk>

Laura J. Bonnett <L.J.Bonnett@liverpool.ac.uk>

Acknowledgements, Conflicts, Ethical Statement

Acknowledgements

Nothing to acknowledge.

# Conflict of interest disclosure

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Ethics and Integrity

Nothing to declare.

Background: Up to 35% of individuals diagnosed with epilepsy proceed to develop pharmacoresistant epilepsy, leading to persistent uncontrolled seizure activity that can directly, or indirectly, significantly degrade an individual's quality of life. The factors underlying pharmacoresistance are unclear, but it has been hypothesised that repeated ictogenic activity is conducive to the development of a more robust epileptogenic network. To ensure that the most effective treatment choices are made and ictogenic activity is minimised, accurate outcome modelling at the point of diagnosis is key. Objectives: This review therefore aims to identify demographic, clinical, physiological (e.g. EEG), and imaging (e.g. MRI) factors that may be predictive of treatment outcomes in patients with newly diagnosed epilepsy (NDE). Data sources, study eligibility criteria, participants, and interventions: MEDLINE and EMBASE were searched for prediction models of treatment outcomes in patients with newly diagnosed epilepsy and any non-surgical treatment plan. Study appraisal and synthesis methods: Study characteristics were extracted and subjected to assessment of risk of bias (and applicability concerns) using the PROBAST tool. Prognostic factors associated with treatment outcomes are reported. *Results:* After screening, 48 models were identified in 32 studies, which generally scored low for concerns of applicability, but universally high for susceptibility to bias. Outcomes reported were heterogenous, but fit broadly into four categories: pharmacoresistance, short-term treatment response, seizure remission, and mortality. Prognostic factors were also heterogenous, but the predictors that were commonly significantly associated with outcomes were those related to seizure characteristics (semiology), epilepsy history, and age at onset. ASM response was often included as a prognostic factor, potentially obscuring factor relationships at baseline. *Conclusions:* Currently, outcome prediction models for NDE demonstrate a high risk of bias. Model development could be improved with a stronger adherence to recommended TRIPOD practices, and by avoiding including response to treatment as a prognostic factor. Implications of key findings: This review identified semiology, epilepsy history, and age at onset as factors associated with treatment outcome prognosis, suggesting that future prediction model studies should focus on these factors in their models. Furthermore, we outline actionable changes to common practices that are intended to improve the overall quality of prediction model development in NDE.

Keywords: newly diagnosed epilepsy, seizures, prognosis, intractability, outcomes, treatment

# Key Points

- This paper presents a systematic literature search for treatment outcome prediction models in newly diagnosed epilepsy.
- The risk of bias in the included models were evaluated using the PROBAST framework, finding a universally high risk level.
- The relationship between semiology, epilepsy history, and age at onset with seizure remission should be examined in future prediction model studies.
- To improve the overall quality of prediction model development in NDE, prospective authors are advised to adhere to TRIPOD guidelines, and to avoid including response to treatment as a prognostic variable.

## Abbreviations

- NDE: Newly Diagnosed Epilepsy
- **PWE: People With Epilepsy**
- ASM: Anti-seizure Medication(s)
- RCT: Randomised Control Trial
- RoB: Risk of Bias
- AC: Applicability Concerns
- TRIPOD(-AI): Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (Artificial Intelligence)
- PROBAST(-AI): Prediction model Risk Of Bias ASsessment Tool (Artificial Intelligence)
- PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses

### Introduction

#### Rationale

#### Clinical overview of epilepsy

As one of the most common neurological diseases, epilepsy is estimated to affect over 70 million people globally.<sup>1,2</sup> Epilepsy incidence tends to be higher in the youngest and oldest age groups, in females, and in low-middle income countries.<sup>3</sup> Epilepsy is characterised by a predisposition to spontaneous seizure activity, which is thought to arise due to abnormalities within cortical networks.<sup>4–7</sup> Epilepsy may refer to any subtype of a multitude of disorders that can differ in seizure type, clinical course, or prognosis; aetiology and comorbidities will also inform the specific diagnoses people with epilepsy (PWE) will receive.<sup>8,9</sup> An accurate diagnosis is crucial for determining the appropriate first-line treatment, which will most commonly be anti-seizure medication (ASM) monotherapy. Alongside seizure activity, PWE are vulnerable to cognitive, behavioural, and neurological comorbidities, the combination of which often result in PWE experiencing a lower quality of life.

#### Newly-diagnosed epilepsy

To better characterise the course of epilepsy and its underlying pathomechanisms, it has been suggested that (people with) newly diagnosed epilepsy (NDE) be studied as a distinct group.<sup>10,11</sup> Studying epilepsy at its earliest time point avoids the confounds inherent in long-standing epilepsy, including the chronic effects of seizure activity and ASM use: seizure activity in chronic epilepsy can cause injuries that encourage the development of pharmacoresistance in PWE, and successive ASM regimens are associated with a reduction in the chance of attaining seizure freedom.<sup>12–15</sup> Predictive models for chronic epilepsy consequently include the confounding variability of seizure and ASM profiles, whereas models developed specifically for use in NDE (which can reliably prognosticate disease trajectories) do not. Models based on NDE cohorts can therefore inform treatment approaches that ameliorate the consequences of epilepsy chronicity.

#### Seizure freedom and pharmacoresistance in First-line Therapies

In a recent large-cohort NDE study, the rate of 1-year remission (cessation of seizure activity)

following ASM mono/polytherapy was 63.7%, and the rate of pharmacoresistance (failure of two or more appropriate ASM trials to control seizure activity) was 36.3%, in line with similar studies.<sup>16–18</sup> ASM considered efficacious for focal seizure management include oxcarbazepine, carbamazepine, and lamotrigine; for generalised seizures, sodium valproate, levetiracetam, lamotrigine, and ethosuximide are common first-line ASM.<sup>19–22</sup> First-line monotherapy represents the best likelihood of preventing seizure recurrence and pharmacoresistance in PWE who have had two seizures or been classified as 'high-risk', and an optimal treatment response is most likely when the appropriate ASM is chosen for monotherapy.<sup>23–26</sup> If a change of ASM is indicated, it is recommended that alternative monotherapy be prescribed.<sup>27</sup> Should this prove unsuccessful, polytherapy, adjunctive therapy, or surgical therapies (i.e. two or more ASM, dietary management, and resection respectively) may be considered.<sup>20</sup>

#### Second-line Therapies

The success of polytherapy is largely dependent on the choice of ASM combination. Combination ASM are often determined based on complementary mechanisms of action, but no specific selection criteria exist, due in part to difficulty in collecting randomised control trial (RCT) data for combination approaches.<sup>18</sup> Should ASM therapy fail, the ketogenic diet is recommended as an adjunctive therapy, and has been found to be effective in encouraging seizure control in people with pharmacoresistant epilepsy, as have invasive techniques of seizure control in focal epilepsies, such as resective surgery, vagus nerve stimulation, deep brain stimulation, and responsive neuromodulation.<sup>28,29</sup> It has been suggested that 12 months after diagnosis is the ideal time at which to evaluate the long-term efficacy of treatment, especially considering the implications for driving restrictions in Europe.<sup>30,31</sup> Furthermore, 12 months is the earliest possible timepoint at which a PWE can be said to have experienced 12 months of continuous seizure freedom, and a referral for surgical therapy is also unlikely.<sup>32,33</sup>

#### **Treatment Outcomes**

Early seizure control has been indicated to be crucial for ensuring optimal treatment outcomes in NDE, putatively due to the prevention of further disruptions to seizure-related networks.<sup>5,34–37</sup> Epilepsy treatment is individualised to ensure that: a) The risk-benefit ratio of a proposed therapy is suitable and b) The PWE is receiving the most efficacious treatment.<sup>27</sup>

The decision to begin a particular regimen is made after the consideration of several potential contraindications, such as pregnancy, medical interactions, and the risk of adverse effects.<sup>38</sup> Importantly, the treatment choice will also be informed by the likelihood of achieving seizure freedom on a particular ASM (the efficacy) and the proportion of PWE who persist with the drug trial (the effectiveness). Predicting treatment outcomes—such as seizure remission, refractoriness, and pharmacoresistance—is non-trivial, also requiring the consideration of factors like age at onset (and the related epilepsy duration), the number of pretreatment seizures, EEG/imaging abnormalities, intellectual impairments, aetiology, and semiology to inform trajectories.<sup>39–42</sup>

#### Prediction models

Prediction models are combinations of prognostic factors used to estimate the risk of a specific endpoint. Built with and validated on large cohorts, prediction models allow for individual patient outcomes to be estimated according to a formal statistical framework.<sup>43</sup> Prognostic and diagnostic models are commonplace in epilepsy care, and the principal benefit of multivariable models (over the use of univariable factors for prediction) is accuracy, especially considering the complexity of epileptic processes.<sup>44,45</sup> Single biomarkers (quantifiable properties indicative of normal biological processes) in epilepsy are thought to lack the granularity and robustness necessary to allow for clinical application.<sup>46</sup> For example, several studies have investigated the relationship between EEG abnormalities and outcomes, often providing conflicting or incongruous evidence; whilst it is probable that some association exists, it is likely that EEG patterns and features influence/are mediated by external factors, and further multivariable research is required to determine how.<sup>47</sup> To facilitate application and future evaluation (as in with systematic reviews) it is recommended that prediction models be designed and reported in a systematic manner, such as is outlined by Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines.<sup>48</sup> Adherence to a predefined set of guidelines, such as TRIPOD, helps to ensure that the risk of bias (RoB; systematic error) and applicability concerns (AC) in the resultant study are kept to a minimum.<sup>49</sup> Several models for the prediction of treatment outcomes in NDE have already been proposed, the latest systematic review of which was published in 2014.<sup>50,51</sup>

#### **Objectives**

RCTs are the gold-standard source for evidence of efficacy and effectiveness for therapies, but it has previously been remarked that there is a lack of suitable high-quality evidence in the literature, with many of the existing studies suffering from methodological flaws.<sup>52</sup> Alternatively, systematic reviews (of prediction models, for example) provide a reliable collation of evidence from which health-based interventions can be informed, without contributing to research waste.<sup>53,54</sup> As new prediction models are developed and validated, it is crucial that they be presented in a format that allows for optimal dissemination of their actionable conclusions. Furthermore, information from previous reviews may be outdated and misleading in the context of more recent findings. The most recent comparable review, carried out by Abimbola et al. in 2014, presents several opportunities for improvement (besides being updated), namely that only studies with samples of over 100 were included and no evaluation of RoB was carried out.<sup>50</sup> A systematic examination of multivariable prediction models for treatment outcomes in NDE was undertaken here to provide an updated and expanded review of the state of the literature, and to facilitate understanding of their conclusions. All included models were evaluated for RoB and AC using the PROBAST (Prediction model Risk Of Bias ASsessment Tool) framework.<sup>49</sup> Between the models, common prognostic factors were identified and are presented herein, with the intention of informing future prediction model studies in NDE.

#### Methods

#### Protocol and registration

This review is reported in adherence with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines, and a non-peer reviewed, publicly available, protocol was registered with PROSPERO (ID: CRD42022329936).<sup>55</sup>

# Eligibility Criteria, Information Sources, Search, Study Selection, and Data Collection Process

MEDLINE and Embase were searched for relevant publications, using PubMed/MeSH (medical subject headings) and Scopus/Boolean terms respectively. Full queries can be seen in Appendix 1. Data were screened by CR and LJB independently, with mediation of any conflicting exclusions following consensus meetings provided by SSK. Studies were included if they contained a multivariable model of treatment outcomes in a discrete sample of NDE,

meeting the following criteria:

- Study design Any primary design including (but not limited to): cohort studies, randomised control trials, quasi-randomised control trials, observational studies, and case-control studies.
- Participants Any person with NDE defined using the operational ILAE definition of two clinically unprovoked seizures, or one unprovoked seizure with a > 60% probability of recurrence (other definitions were evaluated for agreement with the ILAE definition *ad hoc*).<sup>56</sup> Provoked seizures include those deemed situational or due to acute neurological insult/precipitant.<sup>57</sup>
- Multivariable model Prediction models developed with at least two demographic, and/or clinical, and/or neuroimaging, and/or electrophysiological factors collected and assessed as part of standard clinical practice at baseline upon a new diagnosis of epilepsy, that are associated with 12 months continuous seizure freedom (remission). Demographic factors are socioeconomic attributes that can be statistically expressed—for example age, sex, and education level. Clinical factors are signs and symptoms of disease classification or severity including aetiology, type and frequency of seizure, age of onset of epilepsy and duration of illness prior to diagnosis. The neuroimaging and neurophysiological factors include assessments of standard MRI and EEG examinations respectively, often taken upon a new diagnosis of epilepsy.
  - Our search terms were not designed to capture machine learning/artificial intelligence-based studies, due to the complexities introduced by the structure of these models, which is very different to those of regression-based models.<sup>58</sup>
- Primary outcomes 12 months (or longer) continuous seizure freedom (remission). The timeframe of 12 months was chosen in accordance with previous literature suggesting that as one seizure per year is sufficient to preclude PWE from driving, seizure freedom should be measured over the same timeframe.<sup>17</sup> Furthermore, after 12 months of treatment, if seizures are not controlled it has been recommended that the PWE be referred to a specialist clinic.<sup>59</sup>
- Secondary outcomes Reported seizure remission of any duration at any time point; treatment failure (adverse effects, intractability, etc.) reported in any form

#### and at any time.

#### Risk of Bias in Individual Studies

RoB was determined on a per-study basis, using 20 signalling questions over four domains (Participants, Predictors, Outcomes, Analysis); the answers to the questions indicate potential for bias, which then informs the (semi-subjective) potential for bias in that domain. If any domain is flagged as having a high potential for bias, the study is judged to have a high overall RoB.<sup>54</sup> Similarly, three of the four domains contain an AC judgement, whereby the rater evaluates to what extent the study content matches the research question. High concern for applicability in any domain results in the study also receiving a high AC rating.<sup>49</sup> Alongside outcome-related data extraction, data required for RoB and AC assessment were extracted by CR and VP, who independently evaluated all 32 studies in the sample.

Summary Measures, Synthesis of Results, Risk of Bias Across Studies, and Additional Analyses

Data pertinent to describing the setting, methodology, demographics, predictors, and outcomes for individual studies was synthesised into narrative form and evidence tables. Metadata for quality assessments purposes was also extracted. Sankey plots were constructed to visually present the distribution of outcomes across studies, and predictors across outcomes. Definitions for the categories proposed in this study can be found in Appendix 2.

#### Results

#### Study Selection

After the removal of 285 duplicate entries, 878 records were excluded first based on their titles, then abstracts. The remaining 128 reports were sought for retrieval, of which 126 were obtained. The retrieved reports were then assessed for eligibility, during which 77 were excluded due to univariable modelling (44), unsuitable cohorts (20), unsuitable outcomes (12), or absence of primary analysis (1). The remaining reports underwent data extraction, during which 17 were deemed ineligible.<sup>60</sup> Data extraction was carried out on the whole sample by CR and VP independently, using a predefined form to ensure that all relevant information was extracted systematically.

#### Study Characteristics

After screening, 32 studies were deemed suitable for inclusion (for a PRISMA diagram, see Figure 1), including 48 models. 12 studies used prospectively recruited PWE (37.5%), 17 used retrospective data (53.1%), and three used a combination (9.4%). Designs included one case-control study, two RCTs, and 29 cohort studies. Sample sizes ranged from 53 to 99990 PWE, with a median value of 261. Estimates of 'events per variable' ranged from 0.63 to 3927.38, with a median value of 9.86 (for study characteristics, see table 1). In our sample, 12 studies utilised Cox proportional hazards models (37.5%), whereas the remaining 20 employed logistic regressions (62.5%) to build their prediction models. Outcomes were evaluated at timepoints that ranged from 16 - 20 weeks, up to 32 - 36 years, with several studies assessing outcomes at the arbitrary date of the last follow-up.

Figure 1. PRISMA flow diagram of study selection.

Across all models, 41 unique outcomes were operationalised, which were subsequently stratified into four categories (see figure 2): Mortality; Pharmacoresistance; Seizure remission; and Short-term treatment response (a complete list of outcomes is provided in Appendix 3). In accordance with the review objectives, the seizure remission category was used for seizure outcomes of 12 months or longer, with all seizure outcomes of less than 12 months being categorised as short-term treatment response. 69 unique predictors were operationalised, which were subsequently stratified into 11 categories: Age; ASM; Comorbidity; Demographics; Diagnosis; EEG; History; Neuroimaging; Neuropsychology; Response; and Semiology (a complete list of predictors is also provided in Appendix 3). Although unavailable at baseline, response (to treatment) variables were recorded in a number of studies, and contributed significant predictors to several multivariable prediction models.

Table 1. Summary of included studies. Where available, ages are presented in years as mean (SD), \*Median (range), or \*\*Median (IQR). Epilepsy diagnoses are reported as in the original studies.<sup>16,39,42,61–89</sup>

Figure 2. Sankey diagram showing model outcomes across all studies.<sup>16,39,42,61–89</sup>

#### Risk of Bias Within Studies

After PROBAST assessment had reached consensus, nine (28.1%) studies presented with

high AC, whilst all 32 studies demonstrated a high RoB (Table 2). AC for the participant domain were all low, but high for eight studies in the predictor domain, which was related to the inclusion of response to treatment as a prognostic factor. AC was also high for two studies in the outcome domain.<sup>49</sup> RoB was generally low in the participant domain, but universally high in the predictor, outcome, and analysis domains.

Table 2. Summary of the PROBAST risk of bias and applicability concern assessment of the included studies. Responses, in order of low to high risk of bias: Y = yes; PY = probably yes; NI = no information; PN = probably no; N = no. x.a. = Domain applicability; x.b. = Domain risk of bias.<sup>16,39,42,61–89</sup>

#### Results of Individual Studies

In the included studies outcomes were most commonly categorised as short-term treatment response, followed by seizure remission, pharmacoresistance, and then mortality. Across the multivariable models, 112 relationships between predictors and outcomes were found to be statistically significant, with variables from the semiology category being reported as significant most frequently. Response variables were the next most frequent, followed by history and comorbidity. As shown in table 3, there were 40 cases of variables being statistically significant as predictors of seizure remission, of which 13 were categorised as response variables.

Table 3. Summary count of predictor instances, sorted by outcome.

Figure 3. Sankey diagram showing studies and predictors, grouped by outcomes.<sup>16,39,42,61–89</sup>

#### Discussion

#### Summary of Evidence

#### **Review summary**

The authors systematically identified 32 studies that used multivariable prediction models to assess the multifactorial prognosis of treatment outcomes in NDE. NDE is an area of research importance in the exploration of the pathomechanisms underlying the development of an epileptogenic environment, and aside from integrating recent research, this review expands

on previous NDE prediction model reviews in two ways. First, the most recent review by Abimbola et al. in 2014 did not include studies with sample sizes below 100, which this review does.<sup>50</sup> Broadening the inclusion criteria for studies facilitates iteration of the review question over time, and encourages the exploration of specific research questions within the same area. Second, quality (in the form of RoB and AC) assessment of the included studies was carried out by two independent reviewers (CR and VP) in accordance with PROBAST, the first review of epilepsy prediction models to do so.<sup>49</sup> To best meet our primary objective—to inform the prognostic factor choices of future prediction model studies—this report has been prepared in accordance with PRISMA (where appropriate), ensuring maximum transparency, reproducibility, and clarity.<sup>60</sup>

#### Model descriptives

The predictors and the outcomes of the included studies were heterogenous, so were stratified into categories to aid interpretation. The most common outcome was short-term treatment response followed by seizure remission, which aligned with our secondary and primary outcomes of interest, respectively. Models of pharmacoresistance and mortality were also reviewed, which address two of the potential treatment failure outcomes. One fifth (20%) of the studies included in this review included treatment response variables as predictors, which limits the applicability of the resultant models. Although statistical significance does not always confer clinical importance, prediction models are at their most informative when being used to inform treatment initiation, i.e. at baseline/diagnosis. Unsurprisingly, treatment response was often a statistically significant prognostic factor of treatment outcome, and potentially obscured predictive relationships that are interrogatable at baseline - such as treatment decision. In the included studies, seizure characteristics and epilepsy history were frequent statistically significant prognostic factors for seizure remission. For research and prediction model purposes, detailed seizure descriptions and family/personal history factors should be collected at baseline. Furthermore, the consistency of prediction models in epilepsy research would be improved by avoiding convenience-based decisions when designing studies, i.e. using a homogenous, predetermined timepoint, instead of the last follow-up. This could be achieved with the development of a Core Outcome Set for NDE.<sup>90,91</sup>

The models were found to contain a moderate amount of AC, but universally high RoB. Whilst it seems unlikely that models created in a clinical context can be free of RoB, there are steps that can be taken to minimise it - thus increasing the applicability of any resultant models. For example, adherence to the modelling guidelines of TRIPOD by journal editors (similar to CONSORT) and researchers, and nominal acknowledgement of best practices, such as clearly reporting study and model characteristics, would facilitate research communication and uptake.<sup>92</sup> Whilst AC were much less common in the included studies, simple steps such as ensuring consistency between study objectives and methods can be taken to help alleviate them in future studies.

#### Limitations

Whilst all individuals with new-onset epilepsy have (by definition) NDE, the inverse is not true—some PWE may have an undisclosed or unreported history of seizures, extending beyond the recommended 12 month cut-off.<sup>10</sup> In consideration of its distinction from NDE, this review has purposefully avoided misattributing any samples as 'new-onset epilepsy', instead opting for the more verifiable NDE label. With this omission comes a potential loss of specificity that may hamper the accuracy of the presented model to certain PWE; guidelines for reporting seizure histories have been suggested, which should help to prevent this necessity in future reports.<sup>93</sup>

By including only studies involving a discrete sample of ILAE compliant NDE, this review addresses a sample who are not vulnerable to the common confounds of epilepsy research (such as ASM use and chronicity), or the heterogeneity of broader seizure research.<sup>10</sup> However, this specificity comes at the cost of generalisability to provoked seizure research. The exploration of febrile, traumatic, and other acute seizure activity also has the potential to elucidate the pathomechanisms of ictogenesis, with ostensible benefit to unprovoked seizure research. Indeed, the two categories of predictors that were the strongest prognostic factors of epileptic seizure remission in this review, history and semiology, allude to pathomechanistic vulnerabilities (respectively, a predisposition to ictogenesis and the seizure insult) that could potentially describe provocation once fully understood. The conclusions of this review should be weighed against those of reviews into early and first seizures of mixed aetiology, to fully

understand the influence of precipitation on ictogenesis.<sup>57,94</sup>

Machine learning is a rapidly expanding field in the health data sciences, which has demonstrated widespread potential utility.<sup>58</sup> Machine learning prediction models were omitted from this review to ensure the comparability of the included regression model studies, and should not be taken as a dismissal of their increasing value to prognosis and diagnosis. Traditional multivariable models have the potential to inform the design of machine learning models, however, further exploration is necessary to evaluate the current state of machine learning prediction modelling in epilepsy. To facilitate the systematic comparison of artificial intelligence prediction model studies, reporting guidelines (TRIPOD-AI and PROBAST-AI) are in development.<sup>95</sup>

#### Conclusions

The studies included in this review are heterogenous in both predictor and outcome selection, which is a hindrance to systematic comparison. To evaluate their effectiveness, prediction modelling of treatment decisions should be encouraged, whilst the inclusion of response to treatment as a prognostic factor should be avoided. Authors should also attempt to ensure that their studies adhere to reporting guidelines, to reduce RoB and AC.

#### Postscript

#### Acknowledgements

Nothing to acknowledge.

#### **Contributions**

CR: Conceptualisation, investigation, visualisation, writing - original draft preparation, writing - review and editing. ORCID ID: https://orcid.org/0000-0002-3824-1681

VP: Investigation.

AM: Writing - review and editing. ORCID ID: https://orcid.org/0000-0002-6861-8806

SSK: Writing - review and editing, supervision. ORCID ID: https://orcid.org/0000-0001-

## 5247-9795

LJB: Conceptualisation, investigation, writing - review and editing. ORCID ID: https://orcid.org/0000-0002-6981-9212

# Conflict of interest disclosure

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Ethics and Integrity

Nothing to declare.

# References

1. Beghi E. The Epidemiology of Epilepsy. *Neuroepidemiology*. 2020;54(2):185-191. doi:10.1159/000503831

 Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: A meta-analytic approach. *Epilepsia*.
 2010;51(5):883-890. doi:10.1111/j.1528-1167.2009.02481.x

3. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology*. 2017;88(3):296-303. doi:10.1212/WNL.000000000003509

4. Fisher RS, Boas W van E, Blume W, et al. Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia*. 2005;46(4):470-472. doi:10.1111/j.0013-9580.2005.66104.x

5. Terry JR, Benjamin O, Richardson MP. Seizure generation: The role of nodes and networks. *Epilepsia*. 2012;53(9):e166-e169. doi:*10.1111/j.1528-1167.2012.03560.x* 

 Srinivas HV, Shah U. Comorbidities of epilepsy. *Neurology India*. 2017;65(Supplement):S18-S24. doi:10.4103/neuroindia.NI\_922\_16

7. Ridsdale L, Wojewodka G, Robinson E, et al. Characteristics associated with quality of life among people with drug-resistant epilepsy. *Journal of Neurology*. 2017;264(6):1174-1184. doi:10.1007/s00415-017-8512-1

8. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):512-521. doi:10.1111/epi.13709

9. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):522-530. doi:10.1111/epi.13670

Pohlmann-Eden B. Conceptual relevance of new-onset epilepsy. *Epilepsia*. 2011;52
 Suppl 4:1-6. doi:10.1111/j.1528-1167.2011.03142.x

11. Leek NJ, Neason M, Kreilkamp BaK, et al. Thalamohippocampal atrophy in focal epilepsy of unknown cause at the time of diagnosis. *European Journal of Neurology*. 2021;28(2):367-376. doi:10.1111/ene.14565

12. Kreilkamp BAK, McKavanagh A, Alonazi B, et al. Altered structural connectome in non-lesional newly diagnosed focal epilepsy: Relation to pharmacoresistance. *NeuroImage : Clinical*. 2021;29. doi:10.1016/j.nicl.2021.102564

13. Alonazi BK, Keller SS, Fallon N, et al. Resting-state functional brain networks in adults with a new diagnosis of focal epilepsy. *Brain and Behavior*. 2019;9(1):e01168. doi:10.1002/brb3.1168

14. Pohlmann-Eden B, Crocker CE, Schmidt MH. A conceptual framework for the use of neuroimaging to study and predict pharmacoresistance in epilepsy. *Epilepsia*. 2013;54 Suppl 2:75-79. doi:10.1111/epi.12190

15. Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. *Neurology*. 2012;78(20):1548-1554. doi:10.1212/WNL.0b013e3182563b19

16. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. *JAMA neurology*. 2017;75(3):279-286. doi:10.1001/jamaneurol.2017.3949

17. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2010;51(6):1069-1077. doi:10.1111/j.1528-1167.2009.02397.x

18. Verrotti A, Tambucci R, Di Francesco L, et al. The role of polytherapy in the management of epilepsy: Suggestions for rational antiepileptic drug selection. *Expert Review of Neurotherapeutics*. 2020;20(2):167-173. doi:10.1080/14737175.2020.1707668

 Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW, Group
 OBOTEMT. Carbamazepine versus Valproate Monotherapy for Epilepsy: A Meta-analysis. *Epilepsia*. 2002;43(5):505-513. doi:10.1046/j.1528-1157.2002.20801.x 20. Goldenberg MM. Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment. P & T: A Peer-Reviewed Journal for Formulary Management. 2010;35(7):392-415.

21. Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: A network meta-analysis of individual participant data. *The Cochrane Database of Systematic Reviews*. 2017;12:CD011412. doi:10.1002/14651858.CD011412.pub3

22. Kanner AM, Bicchi MM. Antiseizure Medications for Adults With Epilepsy: A Review. *JAMA*. 2022;327(13):1269-1281. doi:10.1001/jama.2022.3880

23. FIRST STG(FIRST). Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group). *Neurology*. 1993;43(3 Pt 1):478-483. doi:10.1212/wnl.43.3 part 1.478

24. Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: A randomised controlled trial. *Lancet* (*London, England*). 2005;365(9476):2007-2013. doi:10.1016/S0140-6736(05)66694-9

25. Kim LG, Johnson TL, Marson AG, Chadwick DW. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: Further results from the MESS trial. *The Lancet Neurology*. 2006;5(4):317-322. doi:10.1016/S1474-4422(06)70383-0

Bonnett LJ, Kim L, Johnson A, et al. Risk of seizure recurrence in people with single seizures and early epilepsy Model development and external validation. *Seizure*. 2022;94:26-32. doi:10.1016/j.seizure.2021.11.007

27. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. *The Lancet Neurology*. 2011;10(5):446-456. doi:10.1016/S1474-4422(11)70047-3

28. Imdad K, Abualait T, Kanwal A, et al. The Metabolic Role of Ketogenic Diets in Treating Epilepsy. *Nutrients*. 2022;14(23):5074. doi:10.3390/nu14235074

29. Janmohamed M, Brodie MJ, Kwan P. Pharmacoresistance - Epidemiology, mechanisms, and impact on epilepsy treatment. *Neuropharmacology*. 2020;168:107790. doi:10.1016/j.neuropharm.2019.107790

30. Bonnett LJ, Marson AG, Johnson A, et al. External validation of a prognostic model for seizure recurrence following a first unprovoked seizure and implications for driving. *PloS One*. 2014;9(6):e99063. doi:10.1371/journal.pone.0099063

31. Epilepsy Action. Driving rules for epilepsy. *Epilepsy Action*. Published online 2023.

32. Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. *Seizure*. 2003;12(7):413-443. doi:10.1016/S1059-1311(03)00047-5

33. Berg AT. Understanding the delay before epilepsy surgery: Who develops intractable focal epilepsy and when? *CNS spectrums*. 2004;9(2):136-144. doi:10.1017/s109285290000849x

34. Shorvon S, Luciano AL. Prognosis of chronic and newly diagnosed epilepsy: Revisiting temporal aspects. *Current Opinion in Neurology*. 2007;20(2):208-212. doi:10.1097/WCO.0b013e3280555175

35. Berg AT. Risk of recurrence after a first unprovoked seizure. *Epilepsia*. 2008;49(s1):13-18. doi:*10.1111/j.1528-1167.2008.01444.x* 

36. Caciagli L, Bernhardt BC, Hong SJ, Bernasconi A, Bernasconi N. Functional network alterations and their structural substrate in drug-resistant epilepsy. *Frontiers in Neuroscience*. 2014;8. doi:10.3389/fnins.2014.00411

37. Engel J, Thompson PM, Stern JM, Staba RJ, Bragin A, Mody I. Connectomics and epilepsy. *Current opinion in neurology*. 2013;26(2):186-194. doi:10.1097/WCO.0b013e32835ee5b8

38. Sharma S, Chen Z, Rychkova M, et al. Treatment initiation decisions in newly diagnosed epilepsyA longitudinal cohort study. *Epilepsia*. 2020;61(3):445-454. doi:10.1111/epi.16439

39. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. *Epilepsy Research*. 2007;75(2-3):192-196. doi:10.1016/j.eplepsyres.2007.06.003

40. Li Z, Cao W, Sun H, et al. Potential clinical and biochemical markers for the prediction of drug-resistant epilepsy: A literature review. *Neurobiology of Disease*. Published online September 2022:105872. doi:10.1016/j.nbd.2022.105872

41. Niriayo YL, Mamo A, Kassa TD, et al. Treatment outcome and associated factors among patients with epilepsy. *Scientific Reports*. 2018;8(1):17354. doi:10.1038/s41598-018-35906-2

42. Zhang Y, Yu N, Su L, Di Q. A prospective cohort study of prognosis for newly diagnosed epilepsy in east China. *BMC Neurology*. 2013;13(1):116. doi:10.1186/1471-2377-13-116

43. Steyerberg EW, Moons KGM, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research. *PLoS Medicine*. 2013;10(2):e1001381. doi:10.1371/journal.pmed.1001381

44. Sansevere AJ, Kapur K, Peters JM, Fernández IS, Loddenkemper T, Soul JS. Seizure Prediction Models in the Neonatal Intensive Care Unit. *Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society*. 2019;36(3):186-194. doi:10.1097/WNP.000000000000574

45. Engel J, Pitkänen A. Biomarkers for epileptogenesis and its treatment. *Neuropharmacology*. 2020;167:107735. doi:10.1016/j.neuropharm.2019.107735

46. FDA-NIH Biomarker Working Group. *BEST (Biomarkers, EndpointS, and Other Tools) Resource*. Food and Drug Administration (US); 2016.

47. Cerulli Irelli E, Leodori G, Morano A, Di Bonaventura C. EEG Markers of Treatment Resistance in Idiopathic Generalized Epilepsy: From Standard EEG Findings to Advanced Signal Analysis. *Biomedicines*. 2022;10(10):2428. doi:*10.3390/biomedicines10102428* 

48. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. *Annals of Internal Medicine*. 2015;162(1):55-63. doi:10.7326/M14-0697

49. Moons KGM, Wolff RF, Riley RD, et al. PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration. *Annals of Internal Medicine*. 2019;170(1):W1-W33. doi:*10.7326/M18-1377* 

50. Abimbola S, Martiniuk ALC, Hackett ML, Glozier N, Mohamed A, Anderson CS. Early predictors of remission in newly diagnosed epilepsy: A systematic approach to reviewing prognostic factor studies. *Neurological Research*. 2014;36(1):1-12. doi:10.1179/1743132813Y.0000000257

51. Mohanraj R, Brodie MJ. Early predictors of outcome in newly diagnosed epilepsy. *Seizure*. 2013;22(5):333-344. doi:10.1016/j.seizure.2013.02.002

52. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. *Epilepsia*. 2006;47(7):1094-1120. doi:10.1111/j.1528-1167.2006.00585.x

53. Higgins JPT, Thomas J, Chandler J, et al., eds. *Cochrane Handbook for Systematic Reviews of Interventions*. 1st ed. Wiley; 2019. doi:10.1002/9781119536604

54. Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Annals of Internal Medicine*. 2019;170(1):51-58. doi:10.7326/M18-1376

55. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Medicine*. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097

56. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE Official Report: A practical clinical definition of epilepsy. *Epilepsia*. 2014;55(4):475-482. doi:10.1111/epi.12550

57. Neligan A, Adan G, Nevitt SJ, et al. Prognosis of adults and children following a first unprovoked seizure. *Cochrane Database of Systematic Reviews*. 2023;(1). doi:10.1002/14651858.CD013847.pub2

58. Dhiman P, Ma J, Andaur Navarro CL, et al. Methodological conduct of prognostic prediction models developed using machine learning in oncology: A systematic review. *BMC Medical Research Methodology*. 2022;22(1):101. doi:10.1186/s12874-022-01577-x

59. Labiner DM, Bagic AI, Herman ST, et al. Essential services, personnel, and facilities in specialized epilepsy centers–revised 2010 guidelines. *Epilepsia*. 2010;51(11):2322-2333. doi:10.1111/j.1528-1167.2010.02648.x

60. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS Medicine*. 2009;6(7):e1000100. doi:*10.1371/journal.pmed.1000100*  61. Aikiä M, Kälviäinen R, Mervaala E, Riekkinen PJ. Predictors of seizure outcome in newly diagnosed partial epilepsy: Memory performance as a prognostic factor. *Epilepsy Research*. 1999;37(2):159-167. doi:10.1016/s0920-1211(99)00059-5

62. Arya R, Gillespie CW, Cnaan A, et al. Obesity and overweight as CAE comorbidities and differential drug response modifiers. *Neurology*. 2016;86(17):1613-1621. doi:10.1212/WNL.00000000002611

63. Ashmawi A, Hosny H, Abdelalim A, Bianchi E, Beghi E. The long-term prognosis of newly diagnosed epilepsy in Egypt: A retrospective cohort study from an epilepsy center in Greater Cairo. *Seizure - European Journal of Epilepsy*. 2016;41:86-95. doi:10.1016/j.seizure.2016.07.016

64. Beydoun A, Sawaya MT, Alam E, Hmaimess G, Ezzeddine K, Younes F. Treatment registry in focal epilepsy (TRIP): Multicenter observational study in Lebanon. *Seizure -European Journal of Epilepsy*. 2015;27:54-59. doi:10.1016/j.seizure.2015.03.001

65. Blank LJ, Acton EK, Willis AW. Predictors of Mortality in Older Adults With Epilepsy: Implications for Learning Health Systems. *Neurology*. 2021;96(1):e93-e101. doi:10.1212/WNL.000000000011079

66. Bruun E, Kälviäinen R, Keränen T. Outcome of initial antiepileptic drug treatment in elderly patients with newly diagnosed epilepsy. *Epilepsy Research*. 2016;127:60-65. doi:10.1016/j.eplepsyres.2016.08.023

67. Cerulli Irelli E, Morano A, Orlando B, et al. Seizure outcome trajectories in a welldefined cohort of newly diagnosed juvenile myoclonic epilepsy patients. *Acta Neurologica Scandinavica*. 2022;145(3):314-321. doi:10.1111/ane.13556

68. Chen RH, Li BF, Wen JH, Zhong CL, Ji MM. Clinical and electroencephalogram characteristics and treatment outcomes in children with benign epilepsy and centrotemporal spikes. *World Journal of Clinical Cases*. 2021;9(33):10116-10125. doi:10.12998/wjcc.v9.i33.10116

69. Dlugos DJ, Buono RJ. Predicting outcome of initial treatment with carbamazepine in childhood focal epilepsy. *Pediatric Neurology*. 2004;30(5):311-315. doi:10.1016/j.pediatrneurol.2003.10.009

70. Dlugos D, Shinnar S, Cnaan A, et al. Pretreatment EEG in childhood absence epilepsy: Associations with attention and treatment outcome. *Neurology*. 2013;81(2):150-156. doi:10.1212/WNL.0b013e31829a3373

71. Dragoumi P, Tzetzi O, Vargiami E, et al. Clinical course and seizure outcome of idiopathic childhood epilepsy: Determinants of early and long-term prognosis. *BMC Neurology*. 2013;13. doi:*10.1186/1471-2377-13-206* 

72. Gasparini S, Ferlazzo E, Beghi E, et al. Family history and frontal lobe seizures predict long-term remission in newly diagnosed cryptogenic focal epilepsy. *Epilepsy Research*. 2013;107(1):101-108. doi:*10.1016/j.eplepsyres.2013.07.004* 

73. Gidey K, Chelkeba L, Gemechu TD, Daba FB. Treatment response and predictors in patients with newly diagnosed epilepsy in Ethiopia: A retrospective cohort study. *Scientific Reports*. 2020;10(1):2465. doi:10.1038/s41598-020-59359-8

74. Hersi H, Saarinen JT, Raitanen J, Peltola J. Response to first antiseizure medication in patients diagnosed with epilepsy. *Acta Neurologica Scandinavica*. 2021;144(1):67-75. doi:10.1111/ane.13426

75. Huang C, Feng L, Li Y, et al. Clinical features and prognosis of epilepsy in the elderly in western China. *Seizure - European Journal of Epilepsy*. 2016;38:26-31. doi:10.1016/j.seizure.2016.03.011

76. Jiang Y, Yuan F, Yang F, et al. Prognostic analysis for short- and long-term outcomes of newly diagnosed epilepsy. *Seizure - European Journal of Epilepsy*. 2017;47:92-98. doi:10.1016/j.seizure.2017.02.018

77. Kessler SK, Shinnar S, Cnaan A, et al. Pretreatment seizure semiology in childhood absence epilepsy. *Neurology*. 2017;89(7):673-679. doi:*10.1212/WNL.00000000004226* 

78. Kim HC, Kim SE, Lee BI, Park KM. Can we predict drug response by volumes of the corpus callosum in newly diagnosed focal epilepsy? *Brain and Behavior*. 2017;7(8):e00751. doi:10.1002/brb3.751

79. Kwong KL, Ting YW, Wong SN, So KT. Acute Seizure-Related Hospitalizations in Children with Newly Diagnosed Epilepsy. *Pediatric Neurology*. 2007;36(5):318-323. doi:10.1016/j.pediatrneurol.2007.01.016

 Li Y, Xia L, Wang Y, Li R, Li J, Pan S. Long-term response and response patterns to antiepileptic drugs in patients with newly diagnosed epilepsy. *Epilepsy and Behavior*. 2021;124. doi:10.1016/j.yebeh.2021.108309

81. Mangunatmadja I, Ismael S, Sastroasmoro S, Suyatna FD, van Nieuwenhuizen O, Cornelis van Huffelen A. Risk factors predicting intractability in focal epilepsy in children under 3 years of age: A cohort study. *Epilepsy and Behavior*. 2021;123:108234:108239. doi:10.1016/j.yebeh.2021.108234

82. Ollivier ML, Dubois MF, Krajinovic M, Cossette P, Carmant L. Risk factors for valproic acid resistance in childhood absence epilepsy. *Seizure*. 2009;18(10):690-694. doi:10.1016/j.seizure.2009.09.007

 Oskoui M, Webster RI, Zhang X, Shevell MI. Factors predictive of outcome in childhood epilepsy. *Journal of Child Neurology*. 2005;20(11):898-904. doi:10.1177/08830738050200110701

84. Park KM, Hur Y, Kim HY, et al. Initial response to antiepileptic drugs in patients with newly diagnosed epilepsy. *Journal of Clinical Neuroscience*. 2014;21(6):923-926. doi:10.1016/j.jocn.2013.10.031

85. Quintana M, Sánchez-López J, Mazuela G, et al. Incidence and mortality in adults with epilepsy in northern Spain. *Acta Neurologica Scandinavica*. 2021;143(1):27-33. doi:10.1111/ane.13349

86. Sharma S, Chen Z, Rychkova M, et al. Short- and long-term outcomes of immediate and delayed treatment in epilepsy diagnosed after one or multiple seizures. *Epilepsy and Behavior*. 2021;117. doi:10.1016/j.yebeh.2021.107880

87. Sillanpää M, Shinnar S. Status epilepticus in a population-based cohort with childhood-onset epilepsy in Finland. *Annals of Neurology*. 2002;52(3):303-310. doi:10.1002/ana.10286

88. Tartara E, Micalizzi E, Scanziani S, Ballante E, Paoletti M, Galimberti CA. Late-Onset Focal Epilepsy: Electroclinical Features and Prognostic Role of Leukoaraiosis. *Frontiers in Neurology*. 2022;13. 89. Yang S, Han X, Wang N, et al. Predicting seizure freedom with AED treatment in newly diagnosed patients with MRI-negative epilepsy: A large cohort and multicenter study. *Epilepsy & Behavior*. 2020;106:107022. doi:10.1016/j.yebeh.2020.107022

90. Mitchell JW, Noble A, Baker G, et al. Protocol for the development of an international Core Outcome Set for treatment trials in adults with epilepsy: The EPilepsy outcome Set for Effectiveness Trials Project (EPSET). *Trials*. 2022;23(1):943. doi:10.1186/s13063-022-06729-4

91. Prinsen CAC, Vohra S, Rose MR, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: Protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a 'core outcome set'. *Trials*. 2014;15:247. doi:10.1186/1745-6215-15-247

92. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement:
Updated guidelines for reporting parallel group randomised trials. *PLoS medicine*.
2010;7(3):e1000251. doi:10.1371/journal.pmed.1000251

93. Wirrell E. Evaluation of First Seizure and Newly Diagnosed Epilepsy. *CONTINUUM: Lifelong Learning in Neurology*. 2022;28(2):230. doi:10.1212/CON.000000000001074

94. Ratcliffe C, Adan G, Marson A, et al. Neurocysticercosis-related Seizures: Imaging Biomarkers. *Seizure*. Published online April 2023. doi:10.1016/j.seizure.2023.04.005

95. Collins GS, Dhiman P, Navarro CLA, et al. Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence. *BMJ Open*. 2021;11(7):e048008. doi:10.1136/bmjopen-2020-048008



Aikiä et al., 1999

Li et al., 2021

Mangunatmadja et al., 2021

Zhang et al., 2013

Oskoui et al., 2005

Hitiris et al., 2007

Yang et al., 2020

Dlugos et al., 2013

Arya et al., 2016

Kessler et al., 2017

Chen et al., 2021

Pharmacoresistance

Short-term Treatment Response

Dlugos and Buono, 2004	
Gidey et al., 2020	
Huang et al., 2016	
Tartara et al., 2022	
Kim et al., 2017 Kwong et al., 2007	
Ollivier et al., 2009	
Dragoumi et al., 2013	
Sharma et al., 2021	
Ashmawi et al., 2016	
Cerulli Irelli et al., 2022	Seizure Remission
Jiang et al., 2017	

Bruun et al., 2016

Chen et al., 2017

Beydoun et al., 2015

Gasparini et al., 2013

Hersi et al., 2021

Sillanpää and Shinnar, 2002

Blank et al., 2021

Mortality

Quintana et al., 2021

		Multiple pretreatment seizure types
Dragoumi et al., 2013		Older at diagnosis
		Higher pretreatment seizure count
		Treated with lamotrigine
	Short-term Treatment Response	History of migraine
Oskoui et al., 2005		Younger at diagnosis
		Family history of epilepsy
		Treated with ethosuxamide
Hitiris et al., 2007		Longer minimum seizure duration
		Status epilepticus
		Presence of epileptiform activity
Yang et al., 2020		Higher pretreatment seizure frequency
		Non-eye automatisms
		Presence of global developmental delay
Aikiä et al., 1999		Presence of epileptogenic lesion
		Recreational drug use
		Presence of GTCS
Dlugos et al., 2013		Nocturnal seizures
		History of febrile seizures
Sharma et al., 2021		Family history of seizures
	Seizure Remission	Non-eye automatisms or myoclonic/atonic/clonic seizures
		Remote symptomatic aetiology Partial complex or mixed seizures
Blank et al., 2021		Impaired short-term memory
		Impaired long-term memory Simple partial seizures
Ashmawi et al., 2016		Female sex
		Hispanic ethnicity
Jiang et al., 2017		Presence of comorbidity  Applicable for Medicaid
		Intermediate urbanisation of residence
Ollivier et al., 2009		Catamenial seizures
		Pretreatment seizures
Cerulli Irelli et al., 2022		Diagnosis of CAE
	Pharmacoresistance	High academic performance
Bruun et al., 2016		<ul> <li>Presence of traumatic brain injury</li> <li>Presence of psychiatric comorbidity</li> </ul>

Semiology

Comorbidity

History

Age

ASM

Demographics

Diagnosis

Neuroimaging

EEG

Neuropsychology

Arya et al., 2016	
Chen et al., 2017	Mortality
Kessler et al., 2017	
Quintana et al., 2021	
Li et al., 2021	
Gasparini et al., 2013	
Gidey et al., 2020	
Mangunatmadja et al., 2021	
Tartara et al., 2022	
Chen et al., 2021	
Zhang et al., 2013	
Beydoun et al., 2015	
Dlugos and Buono, 2004	No significant predictors

Treated with ASM Acute seizure-related hospitalisations Treated with polytherapy Evolution to generalised seizures Evolution to abnormal background rhythm Diagnosis of IGE Advanced age at diagnosis
 Tumor-related aetiology Partial or atonic seizures Presence of auras Presence of leukoaraiosis Presence of neuropsychiatric disorder History of perinatal injury History of CNS insult Posttreatment change in seizure type Spike focus Presence of epilepsy risk factor Frontal focus Shorter EEG bursts Lower corpus callosum volumes Presence of intellectual disability Unkown aetiology



Citation	PWE n=	Epilepsy Diagnosis	Patient age in years (SD)	Outcomes	Outcome Timepoints	Modelling Method	Model Predictors				
Aikiä et al., 1999	89	Partial epileps y	Group 1 (n = 79): 34.40 (15.30) Group 2 (n = 10): 29.20 (12.40)	Refractory seizure disorder	2 years	Logistic regression	Age at diagnosis (Younger = greater ikelihood of poor 2-year outcome) Aetiology (Remote symptomatic = greater ikelihood of poor 2-year outcome) Seizare type (Parialia compker or mixed = greater ikelihood of poor 2-year outcome) Spike focus (Presence = greater ikelihood of poor 2-year outcome) Immodate Ist tread (Imgainment = greater ikelihood of poor 2-year outcome) Delayed ist recognition (Impairment = greater ikelihood of poor 2-year outcome)				
Arya et al., 2016	445 445	Childhood absence epilepsy	7.42 (2.58 - 12.92)*	Freedom from failure Seizure freedom	16 - 20 weeks 16 - 20 weeks	Logistic regression	ASM (LTG = reduced chance of freedom from failure) ASM (LTG = reduced chance of seizure freedom) BMI (ns)				
Ashmawi et al., 2016	287 287	NS	15.60 (11.50)	2-year remission 2-year sustained remission	4 - 20 years 4 - 20 years	Cox proportional hazards	Nocturnal seizures (Yes = reduced chance of sustained 2 year remission) First ASM response (Bad = reduced chance of 2 year remission) First ASM response (Bad = reduced chance of 2 year sustained remission) Family history - epilepsy (ns) Neuroingidael evaluation (ns) Neuroingidael evaluation (ns) Pretreatment seizure number (ns) Seizure types (ns) Aetiology (ns)				
Beydoun et al., 2015	234	Focal epilepsy	31.60 (21.90)	6-month terminal seizure remission at month 12	1 year	Cox proportional hazards	Epileptogenic lesion on neuroimaging (Yes = less likely to experience 6-month terminal remission at month 12) Baseline seizure type (Simple partial = less likely to experience 6-month terminal remission at month 12) Age (ns) Sex (ns)				
Blank et al., 2021	99990	NS	> 65.00	5-year mortality	5 years	Cox regression	Sex (Female = decreased risk of mortality) Race (Asian = decreased risk of mortality) Ethnichy (Hspanic = decreased risk of mortality) Comorbidity (Yes = increased risk of mortality) Medicaid consumance (Yes = increased risk of mortality) Rurai-urban continuum code (Intermediate = increased risk of mortality)				
Bruun et al., 2016	293 293	NS	> 65.00	2-year remission 5-year seizure remission	2 - 5 years 5 years	Cox proportional hazards	Seizure remission within the first year of ASM treatment (No = less likely to attain 2-year remission) Sex (ns) Age at diagnosis (ns) Aeticlogy (ns) Pretroatment EEG (ns) Seizure type (ns) Number of seizure types (ns) Pretroatment seizure number (ns)				
Cerulli Irelli et al., 2022	113 113	Juvenile myoclonic epilapsy	14.00 (10.00 – 16.00)*	4-year seizure remission Delayed sustained remission	9.50 - 27 years 9.50 - 27 years	Multinomial logistic regression	Absence seizures (Present = lowar remission probability) Age at onset (Earlier = remission delay) Catamenial seizures (Present = emission delay) Photosensitivity (ns) Mycolanis tatus eglepticus (ns) Focal EEG asymmetries (ns)				
Chen et al., 2017	1795	NS	33.00 (9.00 - 93.00)*	Terminal seizure outcome	2 - 12 years	Cox proportional hazards	Age at orset (Below 5 = lower likelihood of treatment response) Attack frequency (Higher = lower likelihood of treatment response)				
Chen et al., 2021	106	Benign epilepsy	7.15 (1.82)	Treatment response	1 year	Logistic regression	Seizures in the year prior to treatment (More = poorer chance of seizure freedom) Recreational drug use (Yes = poorer chance of seizure freedom) Family history of epilepsy (More = poorer chance of seizure freedom)				
Dlugos and Buono, 2004	129	Focal epilepsy of presumed temporal lobe origin	Trial failure: 6.20 (4.00) Seizure free: 7.70 (3.90)	CBZ trial failure	1 year	Logistic regression	Early risk factor for epilepsy (Yes = higher chance of trial failure) Temporal neuroimaging abnormality (Yes = higher chance of trial failure)				
Diugos et al., 2013	329 329	Childhood absence epilepsy	NS (2.58 - 12.92)*	Freedom from failure at 16 - 20 weeks Seizure freedom at 16 - 20 weeks	16 - 20 weeks 16 - 20 weeks	Logistic regression	ASM (ETX over LTG = greater chance of freedom from failure) Shortest seizure duration (Longer = greater chance of freedom from failure) ASM (ETX over LTG = greater chance of seizure freedom) Shortest seizure duration (Longer = greater chance of seizure freedom) Age (ns) Valproate vs Ethosuvamide (ns) Occipital intermittent rhythmic delta activity (ns) Focal sharp waves (ns)				
Dragoumi et al., 2013	303 303 303 303 303 303	ldiopathic childhood epilepsy	6.70 (3.00)	12-month remission at 2 years Occurrence of seizure in the initial 12 months Occurrence of seizures in the preceding 2 years at 4 years Occurrence of seizures in the preceding 2 years at study end Remission - relapse pattern	2 years 1 year 4 years < 22 years < 22 years < 22 years	Logistic regression	Diagnosis (CAE = increased chance of remission at 2 years) Response (Early = increased chance of a low currence in the first 12 months) Academic performance (High = decreased chance of seizure occurrence in the first 12 months) Academic performance (High = decreased chance of seizure occurrence in the first 12 months) Response (Early = decreased chance pattern °C) Response (Early = decreased chance pattern °C) Status epipelous (Yes = increased chance of seizure occurrence in the first 12 months) Multiple seizure types (More = increased chance of seizure occurrence in the first 12 months) History - febrics seizures (Yes = increased chance of seizure occurrence in the first 12 months) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 years) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 years) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 years) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 years) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 years) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 years) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 years) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 yeard) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 yeard) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 yeard) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 yeard) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 yeard) History - migraine (Yes = increased chance of seizure occurrence in the preceding 2 years at 4 yeard) Histor				

Multiple seizure types (More = increased chance of pattern 'C') History - migraine (Yes = increased chance of pattern 'C')

Citation	PWE n=	Epilepsy Diagnosis	Patient age in years (SD)	Outcomes	Outcome Timepoints	Modelling Method	Model Predictors
Gasparini et al., 2013	186	Cryptogenic focal epilepsy	39.00 (22.00)	5-year seizure remission	5 - 21 years	Cox proportional hazards	Family history (Epilepsy or febrile seizures = increased chance of remission) Lobe localisation (Front = increased chance of remission)
Gidey et al., 2020	404	NS	27.40 (11.20)	Seizure recurrence	2 - 7 years	Cox proportional hazards	Pretreatment seizure number (Greater = decreased chance of achieving seizure remission) Treatment adherence (Poor = decreased chance of achieving seizure remission)
Hersi et al., 2021	459	NS	45.00 (31.00)**	12-month seizure freedom	1 - 11 years	Binary logistic regression	Sex (Male = more likely to achieve remission) Aetiology (Unknown = more likely to achieve remission) EEG (Epleiption achiry = less likely to achieve seizure freedom) Age at disgrosis (ns) First SM-koloso (ns) First seizure type (ns)
Hitiris et al., 2007	780	NS	31.00 (9.00 - 93.00)	Seizure free for the last 12 months	2.50 - 21 years	Binary logistic regression	Family history - epilepsy (Yes = greater risk of pharmacoresistance) History - febrie seizures (Yes = greater risk of pharmacoresistance) Taurmatic brain injuny (Yes = greater risk of pharmacoresistance) Psychiatric comorbidity (Yes = greater risk of pharmacoresistance) Recreational drug use (Yes = greater risk of pharmacoresistance) More than 10 seizures before treatment (Yes = greater risk of pharmacoresistance) Sex (ns) Neurological deficit (ns) Mental retartication (ns) Seizures for more than one year pretreatment (ns)
Huang et al., 2016	298	NS	70.50 (10.10)	50% seizure reduction	2 years	Logistic regression	Age at onset (Older = more ikely to achieve satisfactory seizure control at 2 years) ASM treatment (Yes = more ikely to achieve satisfactory seizure control at 2 years)
Jang et al., 2017	336 336	NS	11.00 (10.00)**	2-year remission at short-term follow-up 5-year remission at long-term follow-up	5 years 5 - 8 years	Logistic regression	Time to treatment (> 12 months = more likely to experience unfavourable short term outcomes) Seizure frequency in the first year of treatment (> 2 = more likely to experience unfavourable short term outcomes) Sex (ns) Age at onset (ns) Pretreatment seizure density (ns) Multiple seizure types (ns) Status epilepticos (ns) Aetiology (ns) EEG (ns) Neuroimaging (ns)
Kessler et al., 2017	310	Childhood absence epilepsy	NS (2.58 - 12.92)*	Seizure freedom at 16 - 20 weeks	16 - 20 weeks	Logistic regression	Shortest burst duration on baseline EEG (Short = higher chance of seizure freedom) Lamotridgine vs Erbosuxmide (Lamotrighe = lower chance of seizure freedom) Cutster pattern 2 (Yes = lower chance of seizure freedom) Cutster pattern 2/4 (Yes = lower chance of seizure freedom)
Kim et al., 2017	53	Focal epilepsy	35.60 (15.80)	< 6 months of continuous seizure freedom	> 1 year	Logistic regression	Corpus callosum volume (Lower = good ASM response) Age of orset (ns) Predragnosic duration (ns) Pretreatment seizure frequency (ns)
Kwong et al., 2007	121	NS	5.71 (4.58)	Seizure freedom	1.08 - 3 years	Forward logistic regression	Acute seizure-related hospitalisations (Yes = more likely not to acheive seizure-freedom) Age at orset (ns) Seizure frequency at onset (ns) No initial ASM (ns) Initial seizure type (ns) Syndrome (ns) Aetiology (ns) Neurodevelopmental status (ns) Status e pilopticus (ns) History - neoratal seizure (ns) History - feortal seizure (ns) History - feortal seizure (ns) History - feortal seizure (ns)
Li et al., 2021	472	NS	18.90 (14.00)	3-yearseizure freedom	> 3 years	Logistic regression	Seizure types (Multiple = greater chance of poor drug response) Polytherapy (Yes = greater chance of poor drug response) History - perinatal injury (ns)
Mangunatmadja et al., 2021	71	Focal epilepsy	< 3.00	Intractable epilepsy	1.08 - 2.83 years	Forward logistic regression	Seizure-type evolution (Generalisation at study end = greater chance of intractability) Background rhythm evolution (Abnormal at study end = greater chance of intractability)
Ollivier et al., 2009	180 156	Childhood absence epilepsy	7.00 (2.94)	Complete disappearance of absence seizures during VPA treatment Long term seizure freedom	1 - 9 years 1.08 - 9 years	Logistic regression	Age at diagnosis (Older = protective factor against non-responsiveness to VPA) Pretreatment seizure frequency > 10/day (Yes = risk factor for non-responsiveness to VPA) Presence of GTCS (Yes = risk factor for non-responsiveness to VPA)
Oskoui etal., 2005	196 196 196 196	NS	7.60 (3.70)	Lower probability of seizure remission at 12 months Lower probability of seizure remission at 3 months Poor outcom at 12 months Poor outcome at 3 months	1 year 3 months 1 year 3 months	Logistic regression	Diagnosis (IGE = decreased chance of poor outcome at 3 months) More than one seizure type (Yes = increased chance of intractability at 12 months) Seizure recurrence in the 6-12 months post treatment (Yes = increased chance of intractability at 12 months) More than one seizure type (Yes = increased chance of intractability at 3 months) More than one seizure type (Yes = increased chance of opro outcome at 12 months) Global developmental delay anter (Yes = increased chance of opro outcome at 12 months) Seizure recurrence in the 6-12 months (Yes = increased chance of opro outcome at 12 months) More than one seizure type (Yes = increased chance of opro outcome at 12 months) Seizare recurrence in the 6-12 months post treatment (Yes = increased chance of poor outcome at 12 months) More than one seizare type (Yes = increased chance of opor outcome at 3 months)
Park et al., 2014	100	NS	16.00 (1.00 - 77.00)*	Seizure free for the last 6 months	6 months	Logistic regression	Age at onset (16+ = increased chance of being a responder) Pretreatment duration (ns)

Citation	PWE n=	Epilepsy Diagnosis	Patient age in years (SD)	Outcomes	Outcome Timepoints	Modelling Method	Model Predictors
							Pretreatment seizure frequency (ns) Pretreatment seizure density (ns)
Quintana et al., 2021	1 10	NS	52.60 (19.60)	Mortality	3.25 - 5.75 years	Cox proportional hazards	Older age (Higher = increased risk of mortality) Tumor-related etiology (Yes = increased risk of mortality) Generalized seizures (Yes = increased risk of mortality)
Sharma et al., 2021	598 380	NS	39.00 (14.00 - 88.00)*	12-month seizure remission Seizure recurrence	1 - 8 years 1 - 8 years	Cox proportional hazards	Epileptogenic neuroimaging findings (Yes = higher rate of seizure recurrence) Prediagrosis seizure number (5+ higher rate of seizure recurrence; ns for rate of seizure recurrence) Treamerna tpoposal: (Neefred = higher rate of seizure recurrence; ns for remission) Skep status (ns for rate of seizure recurrence) Sex (ns for 12-month remission) Aboriginal or Torres Strait Islander origin (ns for remission) Epilepsy type (ns for remission) Prediagrosis tonic-clonic seizures (ns for remission) Initial use of second-gen ASM (ns for remission)
Sillanpää and Shinnar, 2002	115	NS	< 16.00	5-year terminal remission	32 - 36 years	Cox proportional hazards	Response (Early = increased probability of remission) Seizure type (Partial or atonic = decreased probability of remission) Status epilepticus (Occurrence = lower rate of remission)
Tartara et al., 2022	162	NS	73.20 (7.20)	Seizure freedom	1 - 19 years	Cox proportional hazards	Aetiology (Unknown = lower risk of recurrence) Subjective perceptions a toizure onset (Presence = higher risk of recurrence) Leukoaraiosis (Presence = higher risk of recurrence) Age at orset (rts) Gender (ns)
Yang et al., 2020	543 543	NS	24.86 (12.88)	Seizure freedom at 12 months Seizure freedom at 6 months	1 year 6 months	Cox proportional hazards	Circadian rhythm (Seizures in wake and sleep = poor probability of seizure freedom) Pre-ASM EEG (Epilepititim discharges = poor probability of seizure freedom) Neuropsychiatric disorder (Presence of any = poor probability of seizure freedom) Peintalabrain nipury (Yes = poor probability of seizure freedom) History - CNS infection (Yes = poor probability of seizure freedom)
Zhang et al., 2013	180	NS	19.00 (6.00 - 21.00)*	Poor outcome	> 2 years	Logistic regression	Multiple seizure type (Yes = greater chance of poor outcome) Changes in seizure type during treatment (Yes = greater chance of poor outcome)

Citation	1.a.	1.1.	1.2.	1.b.	2.a.	2.1.	2.2.	2.3.	2.b.	3.a.	3.1.	3.2.	3.3.	3.4.	3.5.	3.6.	3.b.	4.1.	4.2.	4.3.	4.4.	4.5.	4.6.	4.7.	4.8.	4.9.	4.b.	Total.a.	Total.b.
Aikiä et al., 1999	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	NI	Y	Y	Ν	Υ	High	N	Y	Y	NI	Ν	NI	Ν	NI	NI	High	Low	High
Arya et al., 2016	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PY	Y	Y	PY	PN	High	Y	Y	Ν	PN	NI	NI	NI	NI	NI	High	Low	High
Ashmawi et al., 2016	Low	Y	Y	Low	High	Y	Ν	Ν	High	Low	Y	PY	Y	Y	Ν	Y	High	N	Ν	PY	PN	Ν	NI	Ν	NI	NI	High	High	High
Beydoun et al., 2015	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PY	Y	Y	Ν	Y	High	PN	Ν	PY	NI	NI	NI	NI	NI	NI	High	Low	High
Blank et al., 2021	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	Y	Y	Y	Ν	Y	High	Y	Ν	Ν	PN	Y	PN	NI	NI	NI	High	Low	High
Bruun et al., 2016	Low	Y	Y	Low	Low	Y	Ν	Ν	High	Low	Y	Y	Y	Y	Ν	Y	High	PN	Ν	Ν	NI	Y	PN	NI	NI	NI	High	Low	High
Cerulli Irelli et al., 2022	Low	Y	PY	Low	Low	Y	Ν	Y	High	Low	Y	PY	Y	Y	Ν	PY	High	N	Y	Ν	PN	Ν	NI	NI	NI	NI	High	Low	High
Chen et al., 2017	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	Y	Υ	Y	Ν	Y	High	Y	Y	Y	PN	Ν	NI	NI	NI	NI	High	Low	High
Chen et al., 2021	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PY	Y	Y	Ν	Υ	High	N	Ν	Y	PN	Ν	NI	NI	NI	NI	High	Low	High
Dlugos and Buono, 2004	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PY	Υ	Υ	Ν	Y	High	N	Ν	PY	PN	Ν	NI	NI	NI	NI	High	Low	High
Dlugos et al., 2013	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PN	Y	Y	Ν	PY	High	PN	Ν	Ν	PN	NI	NI	Ν	PN	NI	High	Low	High
Dragoumi et al., 2013	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PN	Y	NI	Ν	Υ	High	N	Ν	Y	PN	Ν	NI	Ν	NI	NI	High	Low	High
Gasparini et al., 2013	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PY	Y	Y	Ν	Y	High	N	Ν	Y	PN	Ν	NI	NI	NI	NI	High	Low	High
Gidey et al., 2020	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PY	Y	Y	Ν	Y	High	PY	Ν	Y	PN	Ν	NI	NI	NI	NI	High	Low	High
Hersi et al., 2021	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PY	Y	Y	Ν	Y	High	Y	Y	PY	PN	Y	NI	NI	NI	NI	High	Low	High
Hitiris et al., 2007	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PY	Y	Y	Ν	Y	High	Y	Ν	Y	PN	Y	NI	NI	NI	NI	High	Low	High
Huang et al., 2016	Low	Y	Y	Low	Low	Y	Ν	Y	High	High	Y	PN	Y	Y	Ν	Υ	High	N	Ν	Ν	PN	NI	NI	NI	NI	NI	High	High	High
Jiang et al., 2017	Low	Y	Y	Low	High	Y	N	Ν	High	Low	Y	PN	Y	Y	Ν	Y	High	N	Ν	Y	PN	Ν	NI	NI	NI	NI	High	High	High
Kessler et al., 2017	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	PN	Y	Y	Ν	PY	High	NI	NI	Ν	Ν	NI	NI	Ν	NI	NI	High	Low	High
Kim et al., 2017	Low	PN	Y	High	Low	Y	N	Y	High	Low	Y	PY	Y	Y	Ν	Y	High	N	Y	Y	PN	Y	NI	NI	NI	NI	High	Low	High
Kwong et al., 2007	Low	Y	Y	Low	High	Y	Ν	Ν	High	Low	Y	PY	Y	Y	Ν	PY	High	N	Y	PN	PN	Ν	NI	NI	NI	NI	High	High	High
Li et al., 2021	Low	Y	Y	Low	High	Y	Ν	Ν	High	Low	Y	PN	Y	Y	Ν	Y	High	N	Ν	Y	PN	Ν	NI	NI	NI	NI	High	High	High
Mangunatmadja et al., 2021	Low	Y	Y	Low	High	Y	Ν	Ν	High	High	Y	PN	Y	Y	Ν	Y	High	N	Ν	Y	PN	Ν	NI	NI	NI	NI	High	High	High
Ollivier et al., 2009	Low	Y	Y	Low	High	Y	Ν	Ν	High	Low	Y	PY	Y	Y	Ν	NI	High	N	Ν	ΡY	PN	Ν	NI	NI	NI	NI	High	High	High
Oskoui et al., 2005	Low	Y	Y	Low	High	Y	Ν	Ν	High	Low	Y	PN	Ν	Y	Ν	PN	High	N	Ν	PN	PN	Y	NI	NI	NI	NI	High	High	High
Park et al., 2014	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	PY	PN	Υ	Y	Ν	PN	High	N	Ν	Y	PN	Y	NI	NI	NI	NI	High	Low	High
Quintana et al., 2021	Low	Y	Y	Low	Low	PN	Ν	Y	High	Low	Y	Y	Y	Y	Ν	Y	High	N	Y	Y	PN	Ν	NI	NI	NI	NI	High	Low	High
Sharma et al., 2021	Low	Y	Y	Low	Low	PN	Ν	Y	High	Low	Y	PY	Y	Y	Ν	Y	High	PY	Ν	PN	Ν	Ν	NI	NI	NI	NI	High	Low	High
Sillanpää and Shinnar, 2002	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	Y	Y	Y	Ν	PY	High	N	Ν	PN	Ν	Y	NI	NI	NI	NI	High	Low	High
Tartara et al., 2022	Low	Y	Y	Low	Low	PN	Ν	Y	High	Low	Y	NI	Y	Y	Ν	Y	High	Ν	Y	Y	PN	NI	NI	NI	NI	NI	High	Low	High
Yang et al., 2020	Low	Y	Y	Low	Low	Y	Ν	Y	High	Low	Y	Y	Y	Y	Ν	PN	High	PY	Y	PY	Y	Ν	NI	Ν	PN	NI	High	Low	High
Zhang et al., 2013	Low	Y	Y	Low	High	Y	Ν	Ν	High	Low	Y	PY	Υ	Υ	Ν	Υ	High	N	Ν	PN	Ν	Ν	NI	NI	NI	NI	High	High	High

Predictor Category	Mortality	Pharmacoresistance	Seizure remission	Short-term treatment response	Total
Age	1	1	2	5	9
ASM	0	1	0	6	7
Comorbidity	1	3	1	5	10
Demographics	5	0	1	0	6
Diagnosis	1	1	2	2	6
EEG	0	2	1	2	5
History	0	0	6	4	10
Neuroimaging	0	0	2	5	7
Neuropsychology	0	0	1	0	1
Response	0	1	13	2	16
Semiology	1	6	11	17	35
Total	9	15	40	48	112